Baseline Cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation by Ceesay, M. Mansour et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jinf.2016.04.040
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Ceesay, M. M., Kordasti, S., Rufaie, E., Lea, N., Smith, M., Wade, J., ... Pagliuca, A. (2016). Baseline Cytokine
profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing
intensive chemotherapy or haematopoietic stem cell transplantation. Journal of Infection, 73(3), 280-288. DOI:
10.1016/j.jinf.2016.04.040
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
Accepted Manuscript
Baseline Cytokine profiling identifies novel risk factors for invasive fungal disease
among haematology patients undergoing intensive chemotherapy or haematopoietic
stem cell transplantation
Dr M. Mansour Ceesay, MD (Res), Shahram Kordasti, PhD, Eamaan Rufaie, MSc,
Nicholas Lea, PhD, Melvyn Smith, PhD, Jim Wade, MD, Abdel Douiri, PhD, Ghulam
J. Mufti, DM, Antonio Pagliuca, FRCPath
PII: S0163-4453(16)30134-7
DOI: 10.1016/j.jinf.2016.04.040
Reference: YJINF 3765
To appear in: Journal of Infection
Received Date: 13 February 2016
Revised Date: 16 April 2016
Accepted Date: 20 April 2016
Please cite this article as: Ceesay MM, Kordasti S, Rufaie E, Lea N, Smith M, Wade J, Douiri A,
Mufti GJ, Pagliuca A, Baseline Cytokine profiling identifies novel risk factors for invasive fungal
disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell
transplantation, Journal of Infection (2016), doi: 10.1016/j.jinf.2016.04.040.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Baseline Cytokine profiling identifies novel risk factors 
for invasive fungal disease among haematology patients 
undergoing intensive chemotherapy or haematopoietic 
stem cell transplantation 
 
M. Mansour Ceesay, MD (Res)1, Shahram Kordasti, PhD1, Eamaan Rufaie, MSc1, 
Nicholas Lea, PhD1, Melvyn Smith, PhD2, Jim Wade, MD3, Abdel Douiri, PhD4, 
Ghulam J Mufti, DM1, Antonio Pagliuca, FRCPath1 
 
1 Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust and King’s 
College London, London, SE5 9RS, United Kingdom 
2
 Department of Virology, King’s College Hospital NHS Foundation Trust, SE5 9RS, United Kingdom 
3 Department of Microbiology, King’s College Hospital NHS Foundation Trust, London, SE5 9RS, 
United Kingdom  
4 Department of Public Health Science, King’s College London and NIHR Biomedical Research 
Centre at Guy’s and St Thomas’ NHS Foundation Trust 
 
Word count: 2,395 
Tables: 4 
Supplementary information: 5 figures 
 
 
 
Running title: Baseline cytokine profile predicts IFD 
 
 
 
 
 
 
 
 
Corresponding Author: 
Dr M. Mansour Ceesay,  
Department of Haematological Medicine,  
King's College Hospital NHS Foundation Trust,  
Denmark Hill, London, SE5 9RS, United Kingdom  
Tel: +44 (0) 20 3299 3709, Fax: +44(0) 20 3299 3514 
Email: mansour.ceesay@nhs.net
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
Abstract 
Background 
Invasive Fungal disease (IFD) is a disease of immunocompromised hosts.  
Cytokines are important mediators of innate and adaptive immune system. The aim 
of this study was to identify cytokine profiles that correlate with increased risk of IFD. 
Methods 
We prospectively enrolled 172 adult haematology patients undergoing intensive 
chemotherapy, immunosuppressive therapy, and haematopoietic stem cell 
transplantation. Pro-inflammatory cytokine profiling using 30-plex Luminex assay 
was performed at baseline and during treatment. Nine single nucleotide 
polymorphisms (TLR1, TLR2, TLR3, TLR4.1, TLR4.2, TLR6, CLEC7A, CARD9, and 
INFG) were investigated among transplant recipients and donors. 
Findings 
The incidence of IFD in this cohort was 16.9 % (29/172). Median baseline serum 
concentrations of IL-15, IL-2R, CCL2, and MIP-1α were significantly higher whilst IL-
4 was lower in patients with proven/probable IFD compared to those with no 
evidence of IFD. Baseline high IL-2R and CCL2 were associated with increased risk 
of IFD in the multivariate analysis (adjusted hazard ratio 2.3 [95% CI 1.1 – 5.1; P = 
0.037], and hazard ratio 2.7 [95% CI 1.2 – 6.1; P = 0.016], respectively).  However, 
these differences were not significant in follow up measurements. Similarly, no 
significant independent prognostic value was associated with baseline cytokine 
profile. 
Interpretation 
High baseline IL-2R and CCL2 concentrations were independent indicators of the 
risk of developing IFD and could be used to identify patients for enhanced 
prophylaxis and early antifungal therapy.   
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Key words: Invasive fungal disease, baseline cytokines, IL2R, CCL2 
 
Highlights 
• Baseline cytokine profile appears to provide significant insight into the 
immunological milieu prior to immunosuppressive therapy 
• Baseline IL2R and CCL2 are independent indicators of risk of developing IFD 
• Follow-up cytokine profile may not provide any additional value in IFD risk  
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Introduction 
Invasive fungal disease (IFD) remains an important cause of mortality and morbidity 
among haematology patients undergoing chemotherapy and haematopoietic stem 
cell transplantation (HSCT).1-3 This is largely due to the a defective immune system 
caused by the underlying primary haematological malignancies and their often 
complex treatments.4 IFD caused by moulds such as invasive aspergillosis (IA) are 
notoriously difficult to diagnose in clinical practice and indeed no validated 
standardised criteria exist for this purpose. 
 
The ubiquitous nature of moulds makes human contact almost universal.  Inhalation 
of asexual spores (conidia) brings them into contact with the respiratory 
macrophages and monocytes, which are the first line of defence against IFD.5 These 
effector cells of the innate immune system respond to the presence of the conidia, in 
concert with neutrophils, by a variety of complex mechanisms such as phagocytosis 
and intracellularly destroying conidia, and aggregation around the conidia to prevent 
their germination.5-7  The innate immune system relies on pattern recognition 
receptors (PRR) on the surface of immune cells, which recognise pathogen-
associated molecular patterns (PAMP) on the surface of fungi and many other 
microorganisms.8 The best characterised PAMPs involved in the recognition of fungi 
are Toll-like receptors (TLR) and lectin receptors such as dectin-1.9 The PRR-PAMP 
interaction triggers a cascade of complex intracellular reactions leading to the 
production of pro-inflammatory cytokines such as TNF, IL-1, IL-12 and IL-6 via the 
nuclear factor-κB (NF-κB) pathway.10 This in turn drives CD4+ T-lymphocytes 
towards T helper (Th) 1 and 17 phenotype, an adaptive immune response that 
further augments the innate immune system.9,11 
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Susceptibility to IFD can be partly attributed to defective or ineffective cytokine 
production.  Part of this susceptibility is genetically determined.  For instance, dectin-
1 polymorphism (Y238X, rs6910526) leads to a truncated carbohydrate recognition 
domain, which in turn leads to a defective production of IL-17, TNF, and IL-6 and is 
associated with significantly increased risk of IFD.12,13 Similarly, single nucleotide 
polymorphisms (SNP) in other PAMPs such as TLR2 and TLR4, TLR1 and TLR5 
have been shown to increase the risk of IFD through defective cytokine 
production.14,15 Polymorphisms in other cytokine genes such as IL-10, IL-1, TNF 
receptor type 2 promoter have also been implicated as genetic biomarkers of 
susceptibility to IFD.16-18 However, the prevalence of such SNPs are relatively 
uncommon as the vast majority of IFD patients or stem cell donors do not have any 
identifiable mutation.  It is therefore likely that other yet unidentified mechanisms 
exist which affects an effective cytokine milieu. 
 
As cytokines are key molecules that mediate and regulate effector functions of both 
the innate and adaptive immune systems, we hypothesise that serum cytokine levels 
pre-chemotherapy or HSCT (baseline cytokine profile) and levels during treatment 
may provide a diagnostic and prognostic value.  As part of the Diagnostic and 
Management Strategies for Invasive Aspergillosis Study 19 we examined the role of 
cytokines in IFD as risk and prognostic factors by measuring 30 cytokines on sera at 
baseline and follow-up in a cohort of haematology patients undergoing HSCT or 
intensive chemotherapy.  In addition, we examined nine previously reported 
polymorphisms associated with IFD that influence cytokine biology. 
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Patients and Methods 
Patients 
Study subjects were from the Diagnostic and Management Strategies for Invasive 
Aspergillosis (ClinicalTrials.gov NCT00816088).19 Only adult patients with 
haematological malignancy or aplastic anaemia undergoing intensive chemotherapy 
or HSCT with expected period of neutropenia of more than 10 days were included.  
Details of patient inclusion and exclusion criteria are provided elsewhere.19 Out of 
the 203 recruited patients, 31 were excluded due to fever (6) or initiation of 
chemotherapy prior to sample collection (25) leaving 172 evaluable patients. 
Patients were followed for at least 120 days with median (range) follow-up of 730 
(12-730) days.  The diagnosis of IFD was based on the revised European 
Organization for Research and Treatment of Cancer (EORTC) and the Mycoses 
Study Group (MSG) definitions.20 The study was approved by our local ethics 
committee and conducted in accordance with the Helsinki protocol (2008 revision) 
for medical research involving human subjects and registered with the 
ClinicalTrials.gov (NCT00816088). 
Antifungal, chemotherapy, transplant and IST protocols 
All patients received antifungal drugs according to local protocol previously 
described 21 and summarised here. Itraconazole solution, 200 mg twice/day was 
given as primary prophylaxis to high-risk patients (allogeneic HSCT, AML/MDS and 
salvage lymphoma chemotherapies). Umbilical cord allogeneic HSCT recipients 
were given posaconazole suspension 200 mg three times/day. Autologous HSCT 
recipients received oral fluconazole 200 mg daily. Voriconazole 200 mg twice/day 
was used as secondary prophylaxis. Prophylaxis was initiated at admission and 
continued until unsupported neutrophils were ≥1.0×109/L for two consecutive days 
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and immunosuppression weaned off with no evidence of graft versus host disease 
(GVHD) in the case of allogeneic HSCT recipients. First-line empirical antifungal 
therapy was liposomal amphotericin B (3 mg/kg/day) while voriconazole was used 
for the treatment of proven/ probable IFD.  
Transplant regimens were fludarabine-based with T-cell depletion using either 
antithymocyte globulin (ATG) or alemtuzumab.22 Immunosuppressive therapy for 
aplastic anaemia used the ATG/cyclosporine protocol.23 Chemotherapy regimens 
used were disease dependent and agreed by a multi-disciplinary team. 
Cytokine profiling 
Thirty cytokines (EGF, EOTAXIN, FGF, G-CSF, GM-CSF, HGF, INF-α, IFN-gamma, 
IL-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-
15, IL-17, IP-10, CCL2, MIG, MIP-1α, MIP-1β, RANTES, TNF-α and VEGF) were 
measured using Cytokine 30-plex antibody bead kit (Life technologies, Grand Island, 
NY, USA) using Luminex 200TM (Luminex Corporation, Austin, TX, USA) according 
to the manufacturer’s instructions. Serum concentrations of each cytokine were 
calculated from a control standard curve. The cytokine assays were performed on 
sera (transported on ice and freshly separated and stored at -80ºC until analysis) at 
baseline (before initiation of therapy or fever) and fortnightly during inpatient 
admission.  
Genetic polymorphisms 
Nine single-nucleotide polymorphisms (SNP) were analysed using TaqMan SNP 
Genotyping Assays (Applied Biosystems). Analysis was performed from genomic 
DNA isolated from whole peripheral blood. The following genes / SNP’s (dbSNP ref 
ID) were analysed TLR1 (rs5743611), TLR2 (rs5743708), TLR3 (rs3775291), 
TLR4.1 (rs4986791), TLR4.2 (rs4986790), TLR6 (rs5743810), CLEC7A 
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(rs16910526), CARD9 (rs4077515), and INFG (rs2069705). Samples from 189 
patients (83 allogeneic HSCT recipients, 62 allogeneic donors, and 44 autologous 
HSCT recipients) were genotyped. Genotyping was carried out as described 
previously.13-15,24-27 
Statistical analysis 
Data on baseline serum cytokine concentrations were presented as median (IQR) 
and compared between patients with proven/probable IFD and those with no 
evidence of IFD using the Mann-Whitney U test.  Cox proportional hazards models 
were used to investigate the role of baseline cytokine concentrations as potential 
predictors of IFD. All variables examined in the univariate model with P<0.10 were 
entered in the multivariate model, described elsewhere 19 and included relevant 
cytokines, haematological diagnoses, index haematological treatment, bacteraemia 
during the study period, monocytopenia >10 days, Karnofsky score, and baseline CT 
scan. Significance was assessed by forward stepwise method based on Likelihood 
Ratios.  Adjusted hazard ratios (HR) and 95% CI were calculated. Separate models 
were created for prognostic factors.  The best fit for final model was with IFD and not 
IA.  
Follow-up cytokines were compared graphically by plotting the mean of log 
transformed value per time point, with error bars indicating the 95% CI, according to 
outcome (proven/probable v. evidence of IFD). Patients with possible IFD and not 
classified were excluded from this analysis due to uncertainty of outcome.  
 
The analyses were performed using SPSS statistics version 20 (IBM Corporation, 
New York, USA). P values <0.05 were considered statistically significant. 
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Results 
Baseline cytokines 
Baseline serum cytokine concentrations were available for 172 patients (Table 1). 
The final EORTC/MSG classifications were: proven Aspergillus fumigatus (2) mould 
NOS (1), Fusarium spp. (1), Candida spp. (4), probable IFD (21), possible IFD (14), 
not classified (67), and no evidence of IFD (62). The incidence of proven/probable 
IFD and IA in this cohort was therefore 16.9 % (29/172) and 14.4 % (24/167), 
respectively. Co-infection with bacteraemia occurred in two patients; Micrococcus 
spp. in an allogeneic HSCT recipient with probable IFD and Vancomycin-resistant 
enterococcus in a chemotherapy recipient with proven Aspergillus fumigatus. There 
were four additional patients with bacteraemia who had unclassified IFD but none in 
those with no evidence of IFD.  Twelve patients developed proven/probable IFD 
(Aspergillus fumigatus [1], Fusarium spp. [1], Candida spp. [2], and probable IFD [8]) 
among the allogeneic HSCT patients giving an IFD incidence of 16.9 % (12/71).  
This reflects the incidence in the larger cohort of the study population previously 
described.19  
 
Five cytokines were found to be significantly different between patients with 
proven/probable IFD compared to those with no evidence of IFD.  Median 
concentrations of IL-15, IL-2R, CCL2, and MIP-1α were higher while IL-4 was lower 
in patients with proven/probable IFD compared to those with no evidence of IFD 
(Table 2).   
The role of baseline cytokines as risk factors for IFD was assessed using Cox 
proportional hazard model previously described.19 The median (IQR) CCL2 and IL-
2R concentrations were 419.0 pg/ml (150.2-840.6 pg/ml) and 443.8 pg/ml (297.0- 
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833.6 pg/ml) respectively. Among the 19 patients with CCL2 above the third quartile, 
13 (68.4%) developed IFD compared to 16 of the 72 patients (22.2%) with IL-2R ≤ 
first quartile (Pearson χ2 = 14.78, P<0.001). The adjusted Hazard ratio (HR) for IFD 
in patients with CCL2 >IQR was 2.7 (95% CI 1.2-6.1; P = 0.016).  Of the 24 patients 
with IL-2R >IQR, 13 (54.2%) developed IFD compared to 16 of the 67 patients 
(23.9%) with serum concentrations ≤ IQR (Pearson χ2 = 7.47, P = 0.006).   The 
adjusted HR for IFD in those with IL-2R >IQR was 2.3 (95% CI 1.1-5.1; P = 0.037). 
The adjusted HR  (95% CI) for low IL-4, high MIP-1α, and IL-15 were 2.5 (0.9 – 7.2; 
P = 0.090), 1.7 (0.7 – 4.2; P = 279), and 1.2 (0.5 – 2.9; P = 759), respectively. The 
multivariate model showed that high CCL2 and IL-2R at baseline were independent 
risk factors for developing IFD. 
Follow-up cytokines 
A total of 412 serum follow-up samples from the 172 patients who had evaluable 
baseline patients were analysed. The median number of follow up cytokine samples 
per patient was 2 (range 2-15). Overall no significant differences were detected 
between patients with IFD compared to those with no evidence of IFD 
(Supplementary Figures S1-S5). However, IL-2R was consistently higher in IFD 
patients and appeared to increase with longer follow up (Figure S3). 
Genetic polymorphisms 
A total of 127 patients (median age 53 [range 19-73] years, 76 [60%] male, 83 
allografts and 44 autografts, 111 [87%] white Europeans) were tested for nine SNPs. 
In addition, 62 (67%) donors of allogeneic HSCT were also tested.  Among these 
127 patients 25 were proven/probable IFD, 20 proven/probable IA, 15 possible IFD, 
48 not classified, and 39 had no evidence of IFD. No statistically significant 
differences in any of the genetic polymorphisms were found between IFD cases 
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compared to those with no evidence of IFD (Table 3).  Among donors of allogeneic 
HSCT, no SNP was found in TLR 4.2 (rs4986790, AG D299G) among patients 
with IFD compared to 4 (36.4%) cases in those with no IFD (Table 4). 
Prognostic factors 
Baseline cytokine serum levels were assessed as potential prognostic factors using 
the Cox regression model. A univariate model was created for the 30 cytokines. High 
IL-13 and IL-6 were associated with increased risk of death with odds ratios of 1.8 
(95% CI 1.0-3.4) and 2.4 (95% CI 1.3-4.3) respectively. A multivariate model was 
then created which included IL-6, IL-13, ITU admission, IFD (proven/probable v no 
evidence of IFD), hepatic dysfunction, renal dysfunction (creatinine > 240 umol/L), 
bacteraemia, underlying haematological diagnosis and treatment, which were shown 
to be significant from the larger cohort.  ITU admission, IFD diagnosis, index 
haematological treatment, and renal dysfunction, were significant independent 
prognostic factors. The associated adjusted HR (95% CI) for death were 3.11 (1.03 - 
9.43, P = 0.045), 2.57 (1.03 - 6.40, P = 0.042), 4.51 (0.97 - 21.03, P = 0.055), and 
21.74 (4.59 - 100.00, P = 0.011), respectively. Neither IL-6 nor IL-13 had any 
significant independent prognostic value.    
Discussion 
Cytokines and chemokines, produced by an array of immune cells, form an important 
component of host defences against infection by various pathogens.   Soluble IL-2R, 
produced primarily by activated T-cells, is a marker of antigenic stimulation but high 
baseline levels may represent an ineffective adaptive immune response.28 CCL2 is 
an important chemo-attractant for monocytes and dendritic cells especially in 
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neutropenic setting.29 In this study we demonstrated the usefulness of measuring 
baseline cytokines from peripheral blood (minimally invasive and convenient) as 
independent risk factors for IFD. 
 
IFD is a disease of the immunocompromised and many risk factors have been 
described.30-32 Recently we described additional risk factors such as baseline CT 
abnormalities, prolonged monocytopenia, and poor performance status.19 IL-2R and 
CCL2 at baseline are novel signalling pathways indicating risk of IFD.  
 
IL-2 is produced primarily by activated CD4+ T-cells and activates a number of key 
cells in the immune system in both autocrine (stimulation and expansion of antigen-
specific T cells) and paracrine (effect on B cells, natural killer cells, neutrophils, 
monocytes) manner via the IL-2R.28 Soluble IL-2R is a truncated form of the IL-2R α 
subunit but retains the ability to bind IL-2 efficiently.33,34 Elevated sIL-2R levels have 
been found in autoimmune diseases, malignancies especially adult T-cell 
leukaemia/lymphoma and hairy cell leukaemia, and infections such as tuberculosis 
and brucellosis.28,35 The biological role of sIL-2R in all these conditions as well as in 
IFD is likely to be one of immunosuppression through competitive binding of IL-2 and 
thus curtailing an effective adaptive immune response against the fungus or the 
malignant clone. The competitive binding of IL-2 by sIL-2R may explain the lack of 
difference in our cohort between patients with proven/probable IFD and those with 
no evidence of IFD in our cohort. 
CCL2 was first identified as a monocyte chemoattractant and was initially named 
monocyte chemoattractant protein-1 (MCP-1).36 High levels have been linked to the 
pathogenesis and spread of many cancers such as prostate, breast, and colorectal 
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cancer.37-39 CCL2 is thought to stimulate the tumour microenvironment by a variety 
of mechanisms including direct stimulation of the tumour cells while preventing an 
effective immune response.40,41 This ineffective immune response is likely to underlie 
increased IFD in haematology patients with high baseline CCL2. This effect is 
independent of monocytopenia, which occurs during follow-up after the 
administration of chemotherapy or immunosuppressive therapy. 
It could be argued that the cytokine milieu that predict IFD is non-specific for fungal 
pathogens as the signaling pathway involved in cytokine biology is shared with other 
micro-organisms such as bacteria.  However, the limited number of bacteraemias (6 
cases) in this study makes it difficult to assess the role of cytokines in bacterial 
sepsis especially as these were co-infections.  Larger studies involving greater 
numbers of bacteraemia cases will be required to address this association.  
Follow-up cytokine assays were performed on 412 samples with a median of 2 
(range 2-15) samples per patient collected on a fortnightly basis.  This skew to the 
left is a reflection of the fewer measurements being available in later time points as 
patients engraft and get discharged from hospital.  No significant differences were 
apparent between patients with proven/probable IFD compared to those with no 
evidence of IFD.  More frequent sampling may have detected a pattern of cytokines 
that differentiate between IFD v no evidence of IFD but this will require further 
evaluation.  The lack of difference may also reflect the fact that cytokines are mainly 
an innate immune response and as such lack specificity for fungal infection at a time 
when patients may be having additional inflammatory challenges from 
chemotherapy, donor cell infusion, as well as fever from non-IFD cases.  An 
additional explanation may be the fact that the ineffective immune system that 
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enabled IFD at baseline such as the high levels of the immunosuppressant sIL-2R 
may no longer be relevant during follow-up. 
 
Chai et al investigated 119 patients with IA from the Global Comparative 
Aspergillosis Study 42 and found high baseline IL-8 and persistently elevated IL-6 
and CRP as poor prognostic factors.43 Important differences exist between that study 
and the current one.  Firstly, the Global Comparative Aspergillosis Study was a 
clinical trial comparing voriconazole v amphotericin B and the case definitions for 
proven and probable IA were based on earlier EORTC/MSG 2002 definitions.44 
Secondly, there was no comparator arm in that trial as the study entry criterion was 
proven/probable IA.  It is therefore difficult to assign the cytokine dynamics to IA.  
Thirdly, the baseline values in that study refers to IA prior to initiation of antifungal 
therapy, which is in contrast to true baseline values in the current study where the 
patients showed no clinical or biochemical signs of sepsis and prior to 
chemotherapy, transplant or IST. Finally, the persistently high CRP and IL-6 after 
initiation of antifungal therapy may mean that the affected patients were not 
responding to therapy. This is especially relevant in a disease that is difficult to 
diagnose and the majority of patients were probable cases, some of which would be 
unclassified on the revised EORTC/MSG definitions. 
 
Genetic predisposition to IFD has generated a lot of interest recently.12-14,18,45-47 The 
selection of nine genes to examine for this susceptibility was based on these studies. 
No statistically significant associations were found between these previously 
described SNPs and susceptibility to IFD in our cohort.  The reason for this is likely 
to be due to sample size and/or the small number of IFD cases in the cohort. 
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In conclusion, we have demonstrated that high baseline IL-2R and CCL2 are 
independent indicators of the risk of IFD. High serum levels may reflect ineffective 
immune environment, which in concert with further immunosuppression during 
haematological treatment could lead to increased incidence of IFD. Although we 
used the 30-plex approach, the 2 cytokines can be incorporated into routine 
biochemistry laboratories. 
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Table 1: Baseline demographic and clinical characteristics of study patients 
Characteristic Patients N = 172 
Age, median (range)- years 54 (19 - 74) 
Sex – n (%) 
   Males  
   Females  
 
102 (59) 
70 (41) 
Underlying disease 
   MDS/AML 
   Non-Hodgkin lymphoma 
   Multiple myeloma 
   Aplastic anaemia 
   Acute Lymphoblastic Leukaemia 
   Hodgkin lymphoma 
   Myeloproliferative neoplasms 
 
69 (40) 
29 (17) 
43 (25) 
17 (10) 
4 (2) 
4 (2) 
6 (4) 
Haematological treatment 
   Allogeneic HSCT 
   Autologous HSCT 
   Chemotherapy - only  
   Immunosuppressive therapy - only 
 
71 (41) 
62 (36) 
30 (18) 
9 (5) 
EORTC/MSG classification 
   Proven mould 
   Proven candida 
   Probable IFD 
   Possible IFD 
   Not classified 
   No evidence of IFD 
 
4 (2) 
4 (2) 
21 (12) 
14 (8) 
67 (39) 
62 (36) 
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Table 2: Baseline cytokine profile  
Cytokine  IFD N= 29 no IFD N=62 Mann-
Whitney p-
value Median IQR Median IQR 
EGF 65.1    21.6-208.4 82.4 29.5-218.1 0.285 
EOTAXIN 74.7 31.0-150.0 63.4 37.8-100.6 0.740 
FGF 14.6 5.5-27.4 13.0 9.2-22.5 0.692 
GCSF 69.0 29.4-267.1 43.1 25.2-231.0 0.450 
GMCSF 20.4 20.3-24.1 20.4 19.7-24.1 0.696 
HGF 400.2 176.7-1346.1 179.2 67.9-829.8 0.071 
IFN-α 27.7 20.3-48.1 23.6 19.1-34.3 0.259 
IFN-γ 19.6 17.3-39.2 19.3 17.3-37.7 0.562 
IL-10 8.4 6.0-10.9 9.4 5.8-13.1 0.762 
IL-12 112.4 76.7-260.1 146.1 87.1-213.7 0.512 
IL-13 27.4 25.7-49.4 25.7 20.7-35.6 0.223 
IL-15 29.5 19.2-64.9 20.9 7.4-29.5 0.035 
IL-17 16.9 10.6-16.9 16.9 11.8-17.1 0.243 
IL-1β 16.9 9.8-19.2 14.1 9.8-16.9 0.303 
IL-1RA 362.7 167.4-696.2 266.3 192.2-640.2 0.851 
IL-2 6.7 4.8-13.7 6.4 5.0-9.9 0.746 
IL-2R 616.7 322.3-1208.9 411.3 284.1-730.8 0.039 
IL-4 9.0 4.0-36.1 33.8 9.0-51.6 0.010 
IL-5 7.0 2.6-7.0 7.0 3.4-7.0 0.632 
IL-6 7.9 3.4-30.7 7.9 4.4-15.3 0.645 
IL-7 15.1 6.7-27.3 24.9 6.5-28.9 0.746 
IL-8 86.9 51.6-470.2 64.2 27.3-284.5 0.193 
IP-10 44.1 23.2-169.3 43.9 26.1-75.1 0.676 
CCL2 785.8 353.2-1421.8 333.5 144.9-620.8 0.003 
MIG 85.9 43.2-168.5 85.9 52.4-182.2 0.925 
MIP-1α 37.2 25.2-125.0 28.6 20.2-48.1 0.049 
MIP-β 70.5 37.0-136.0 65.2 44.9-133.2 0.939 
RANTES 3609.6 600.7-7622.6 6510.0 4958.2-8300.0 0.074 
TNF-α 4.8 4.0-7.3 4.6 2.3-7.3 0.426 
VEGF 15.9 3.7-22.0 22.0 3.6-29.8 0.453 
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Table 3: Association between genetic polymorphisms and IFD in patients  
 IFD No IFD P value 
TLR1 N=63 
   Major allele (C/C) n=57 
   Minor allele (G/G) n=2 
   Major/Minor (C/G  n=4 
   Any SNP (C/G or C/G) n=6 
 
21 (84.0) 
2 (8.0) 
2 (8.0) 
4 (16.0) 
 
36 (94.7) 
0 
2 (5.3) 
2 (5.3) 
 
0.182 
 
 
0.156 
TLR2 n=58 
   Major allele (G/G) n=50 
   Minor allele (A/A)n=0 
   Major/Minor G/A n=8 
   Any SNP (G/A, A/A) n=8 
 
18 (81.8) 
0 
4 (18.2) 
4 (18.2) 
 
32 (88.9) 
0 
4 (11.1) 
4 (11.1) 
 
0.449 
 
 
0.449 
TLR3 n=63 
   Major allele (C/C) n=40 
   Minor allele (T/T) n=3 
   Major/Minor (C/T) n=20 
   Any SNP (C/T, T/T) n=23 
 
17 (68.0) 
0  
8 (32.0) 
8 (32.0) 
 
23 (60.5) 
3 (7.9) 
12 (31.6) 
15 (39.5) 
 
0.349 
 
 
0.547 
TLR4.1 n=62 
   Major allele (C/C) n=54 
   Minor allele (T/T) n=0 
   Major/Minor (C/T) n=8 
   Any SNP (C/T or T/T) n=8 
 
22 (88.0) 
0 
3 (12.0) 
3 (12.0) 
 
32 (86.5) 
0 
5 (13.5) 
5 (13.5) 
 
0.862 
 
 
0.862 
TLR4.2 n=60 
   Major allele (A/A) n=52 
   Minor allele (G/G) n=0 
   Major/Minor (A/G) n=8 
   Any SNP (G/G or A/G) n=8 
 
18 (81.8) 
0 
4 (18.2) 
4 (18.2) 
 
34 (89.5) 
0 
4 (10.5) 
4 (10.5) 
 
0.401 
 
 
0.401 
TLR6 n=61 
   Major allele (G/G) n=29 
   Minor allele (A/A) n=6 
   Major/Minor (G/A) n=26 
   Any SNP (G/A or A/A) n=32 
 
13 (54.2) 
3 (12.5) 
8 (33.3) 
11 (45.8) 
 
16 (43.2) 
3 (8.1) 
18 (48.6) 
21 (56.8) 
 
0.484 
 
 
0.404 
CLEC7A (dectin-1) n=61 
   Major allele (A/A) n=51 
   Minor allele (C/C) n=0 
   Major/Minor (A/C) n=10 
   Any SNP (A/C or C/C) n=10 
 
20 (83.3) 
0 
4 (16.7) 
4 (16.7) 
 
31 (83.8) 
0  
6 (12.2) 
6 (12.2) 
 
0.963 
 
 
0.963 
CARD9 n=60 
   Major allele (C/C) n=15 
   Minor allele (T/T) n=13 
   Major/Minor (G/T) n=32 
   Any SNP (G/T or T/T) n=45 
 
7 (31.8) 
2 (9.1) 
13 (59.1) 
15 (68.2) 
 
8 (21.1) 
11 (28.9) 
19 (50.0) 
30 (78.9) 
 
0.183 
 
 
0.353 
INFg n=64 
   Major allele (G/G) n=5 
   Minor allele (A/A) n=26 
   Major/Minor (G/A) n=33 
   Any SNP (G/A or G/A) n=59 
 
3 (12.0) 
9 (36.0) 
13 (52.0) 
22 (88.0) 
 
2 (5.1) 
17 (43.6) 
20 (51.3) 
37 (94.9) 
 
0.566 
 
 
0.318 
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Table 4: Association between genetic polymorphisms and IFD in allogeneic HSCT 
donors 
 IFD No IFD P value 
TLR1 N=29 
   Major allele (C/C) n=25 
   Minor allele (G/G) n=0 
   Major/Minor (C/G n=4 
   Any SNP (C/G or C/G) n= 4 
 
15 (93.8) 
0 
1 (6.2) 
1 (6.2) 
 
10 (76.9) 
0 
3 (23.1) 
5 (23.1) 
 
0.191 
 
 
0.191 
TLR2 n=28 
   Major allele (G/G) n=27 
   Minor allele (A/A) n=0 
   Major/Minor G/A n=1 
   Any SNP (G/A, A/A) n=1  
 
15 (100) 
0 
0 
0 
 
12 (92.3) 
0 
1 (7.7) 
1 (5.6) 
 
0.274 
 
 
0.274 
TLR3 n=26 
   Major allele (C/C) n=14 
   Minor allele (T/T) n=1 
   Major/Minor (C/T) n=11 
   Any SNP (C/T, T/T) n=12 
 
6 (42.9) 
1 (7.1) 
7 (50) 
8 (57.1) 
 
8 (66.7) 
0 
4 (33.3) 
4 (33.3) 
 
0.375 
 
 
0.225 
TLR4.1 n=28 
   Major allele (C/C) n=23 
   Minor allele (T/T) n=1 
   Major/Minor (C/T) n=4 
   Any SNP (C/T or T/T) n=5  
 
14 (93.3) 
0 
1 (6.7) 
1 (6.7) 
 
9 (69.2) 
1 (7.7) 
3 (23.1) 
4 (30.8) 
 
0.228 
 
 
0.097 
TLR4.2 n=24 
   Major allele (A/A) n=20 
   Minor allele (G/G) n=1 
   Major/Minor (A/G) n=3 
   Any SNP (G/G or A/G) n=4  
 
13 (100) 
0 
0 
0 
 
7 (63.6) 
1 (9.1) 
3 (27.3) 
4 (36.4) 
 
0.059 
 
 
0.017 
TLR6 n=26 
   Major allele (G/G) n=13 
   Minor allele (A/A) n=6 
   Major/Minor (G/A) n=7 
   Any SNP (G/A or A/A) n=13  
 
9 (60) 
4 (26.7) 
2 (13.3) 
6 (40) 
 
4 (36.4) 
2 (18.2) 
5 (45.5) 
7 (63.6) 
 
0.188 
 
 
0.234 
CLEC7A (dectin-1) n=31 
   Major allele (A/A) n=27 
   Minor allele (C/C) n=2 
   Major/Minor (A/C) n=2 
   Any SNP (A/C or C/C) n=4  
 
13 (92.9) 
0  
1 (7.1) 
1 (7.1) 
 
14 (82.4) 
2 (11.8) 
1 (5.9) 
3 (17.6) 
 
0.414 
 
 
0.385 
CARD9 n=26 
   Major allele (C/C) n=12 
   Minor allele (T/T) n=3 
   Major/Minor (G/T) n=11 
   Any SNP (G/T or T/T) n=14  
 
6 (40) 
2 (13.3) 
7 (46.7) 
9 (60) 
 
6 (54.5) 
1 (9.1) 
4 (36.4) 
5 (45.5) 
 
0.760 
 
 
0.462 
INFg n=25 
   Major allele (G/G) n=6 
   Minor allele (A/A) n=3 
   Major/Minor (G/A) n=16 
   Any SNP (G/A or G/A) n=19  
 
2 (16.7) 
2 (16.7) 
8 (66.7) 
10 (83.3) 
 
4 (30.8) 
1 (7.7) 
8 (61.5) 
9 (69.2) 
 
0.618 
 
 
0.409 
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Highlights 
• Baseline cytokine profile appears to provide significant insight into the 
immunological milieu prior to immunosuppressive therapy 
• Baseline IL2R and CCL2 are independent indicators of risk of developing IFD 
• Follow-up cytokine profile may not provide any additional value in IFD risk  
 
